Carsgen's allogeneic cd38 car-t therapy administers first dose in an investigator-initiated trial

Shanghai , jan. 20, 2025 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on innovative car t-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that kj-c2320, an allogeneic car t-cell therapy targeting cd38, has administered the first dose to a patient in an investigator-initiated trial (iit). kj-c2320 is developed based on carsgen's thank-ucar® platform.
CAR Ratings Summary
CAR Quant Ranking